Favorable outcome of SARS-CoV-2 infection in a patient with pituitary insufficiency
DOI:
https://doi.org/10.31053/1853.0605.v77.n4.29997Keywords:
hypopituitarism, covid-19, telemedicine, hydrocortisoneAbstract
Background: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) outbreak originated in Wuhan (China) rapidly turned into a pandemic. Due to a national compulsive decree of quarantine, office visits for chronic disease control were delay.
Hypopituitarism includes all clinical conditions that result in partial or complete failure of the pituitary gland's ability to secrete hormones. Pituitary insufficiency per se has been associated with an increase in both morbidity and mortality, particularly due to cardiovascular disease, which is an important risk factor for COVID-19 disease severity.
Objective: To report the first case of SARS-CoV-2 infection in a patient with hypopituitarism, discuss the implications of the treatments the patient was taking and grade up the value of telemedicine in the present scenario.
Methods: Report of the clinical record of a patient with hypopituitarism and infection with SARS-CoV-2.
Results: During the span of the infection, the patient remained on the same hormonal therapeutic scheme (thyroid, gonadal and adrenal axis). The dose of hydrocortisone was not changed during the course of the infection as she was asymptomatic. We use telemedicine to control and advise her on the treatment.
Conclusion: Health care professionals should carefully follow up on the evolution of patients with hypopituitarism to provide them a safer outcome. The use of telemedicine as a methodology for selected patients acquires relevance in the present epidemiological context.
Downloads
References
-Wu Z, McGoogan JM. Characteristics of and Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020. doi:10.1001/jama.2020.2648
-WHO announces COVID-19 outbreak a pandemic. In: http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/3/whoannounces-covid-19-outbreak-a-pandemic; Downloaded: April 2020
-Fleseriu M, Buchfelder M, Cetas JS, Fazeli PK, Mallea-Gil SM, Gurnell M, et al. Pituitary society guidance: pituitary disease management and patient care recommendations during the COVID-19 pandemic-an international perspective. Pituitary 2020; 23:327-337
-Higham CE, Johannsson G, Shalet SM. Hypopituitarism. Lancet 2016; 388: 2403-2415
-Rockwell KL, Alexis S. GilroyA. Incorporating Telemedicine as Part of COVID-19 Outbreak Response Systems. Am J Manag Care. 2020;26 (4):147-148
-Mongioì L, Barbagallo F, Rosita A, Condorelli R, Cannarella R, Aversa A, et al. Possible long-term endocrine-metabolic complications in COVID-19: lesson from the SARS model. Endocrine. 2020; 68 (3): 467-470
- Pal R, Banerjee M. COVID-19 and the endocrine system: exploring the unexplored. J Endocrinol Invest. 2020; 43 (7): 1027-1031
-Fleseriu M, Hashim IA, Karavitaki N, Melmed S, Murad MH, Salvatori R, et al. Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline.J Clin Endocrinol Metab. 2016; 101 (11):3888-3921
-Wheatland R, Molecular mimicry of ACTH in SARS-implications for corticosteroid treatment and prophylaxis. Med. Hypoth. 2004; 63: 855–862
- RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med. 2020 Jul 17. doi: 10.1056/NEJMoa2021436
- Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, Aliano JL et al. Evidence that vitamin D supplementation could reduce the risk of influenza and COVID-19 infections and death. Nutrients 2020;12: 988
- Hastie CE, Mackay DF, Ho F, Celis-Morales CA, Katikireddi SV, Niedzwiedz CL. Vitamin D concentrations and COVID-19 infection in UK Biobank. Diabetes Metab Syndr 2020;14: 561-565 doi: 10.1016/j.dsx.2020.04.050. Epub 2020 May 7
- Castiglione V, Chiriacò M, Emdin M, Taddei S, Vergaro G. Statin therapy in COVID-19 infection. Eur Heart J Cardiovasc Pharmacother 2020;6: 258-259 doi:10.1093/ehjcvp/pvaa042
- Fedson DS, Rordam OM. Treating Ebola patients: a “bottom up” approach using generic statins and angiotensin receptor blockers. Int J Inf Diseas 2015;36: 80-84
- Fedson D, Fedson DS. Treating influenza with statins and other immunomodulatory agents. Antivir Res 2013; 99:417-435
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Universidad Nacional de Córdoba
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The Faculty of Medical Sciences Journal (RFCM) subscribes to the Open Access policy and does not charge authors fees for publishing, nor does it charge readers fees for accessing published articles (APC).
